1.
Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer, Claudia Ferrara, Kevin Brady, Sabine Lang, Marina Bacac, Ekkehard Mössner, Pablo Umana, Christian Klein. GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. haematol [Internet]. 2018Feb.1 [cited 2021Dec.7];103(2):e78-e81. Available from: https://haematologica.org/article/view/8369